ICU Medical, Inc. (NASDAQ:ICUI) Given Average Recommendation of “Buy” by Brokerages

ICU Medical, Inc. (NASDAQ:ICUI) has been assigned a consensus recommendation of “Buy” from the six research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $168.00.

Several equities analysts have recently weighed in on the stock. Needham & Company LLC raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a report on Wednesday, May 27th. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Jefferies Financial Group raised shares of ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Piper Sandler cut their target price on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Finally, KeyCorp cut their target price on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating for the company in a report on Monday, April 27th.

Insider Buying and Selling at ICU Medical

In related news, VP Virginia Ruth Sanzone sold 2,447 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the sale, the vice president owned 19,460 shares of the company’s stock, valued at approximately $2,414,596.80. The trade was a 11.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the sale, the director directly owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. The trade was a 23.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ICU Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in ICUI. AQR Capital Management LLC increased its holdings in ICU Medical by 2.5% in the 1st quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock worth $1,297,000 after acquiring an additional 229 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in ICU Medical by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier’s stock worth $1,772,000 after acquiring an additional 560 shares in the last quarter. United Services Automobile Association purchased a new stake in ICU Medical in the 1st quarter worth $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in ICU Medical by 32.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier’s stock worth $9,472,000 after acquiring an additional 16,680 shares in the last quarter. Finally, Intech Investment Management LLC increased its holdings in ICU Medical by 38.6% in the 1st quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier’s stock worth $1,658,000 after acquiring an additional 3,326 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Price Performance

NASDAQ:ICUI opened at $137.48 on Tuesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.34 and a quick ratio of 1.17. The firm has a market cap of $3.44 billion, a price-to-earnings ratio of 74.31, a price-to-earnings-growth ratio of 1.91 and a beta of 0.77. The company has a 50 day moving average price of $126.86 and a 200-day moving average price of $138.66. ICU Medical has a 1-year low of $107.00 and a 1-year high of $160.29.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share for the quarter, beating the consensus estimate of $1.78 by $0.19. The firm had revenue of $525.77 million during the quarter, compared to analyst estimates of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The business’s quarterly revenue was down 12.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Equities research analysts forecast that ICU Medical will post 6.5 EPS for the current year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.